XOMA (XOMA) Stock Forecast & Price Target

XOMA Royalty is forecasted to achieve profitable revenue growth in the coming years, with a diversified portfolio of over 120 royalty-bearing partnerships. The recent acquisition of BioInvent's stake in mezagitamab, along with the potential for future acquisitions, highlights the company's ongoing focus on expanding its royalty opportunities. Additionally, XOMA's partnership with Takeda for mezagitamab positions the company to potentially benefit from a significant unmet need in IgA Nephropathy. Long-term value drivers such as the potential Phase 3 data for Osavamator in MDD and the ongoing immune thrombocytopenia (ITP) trial for mezagitamab provide a positive outlook for potential royalty revenue.

XOMA Royalty is a biotechnology company that has a negative outlook due to multiple reasons. The company's EPS may not add up to full year based on rounding and increases in share count, and its quarterly EPS may not add up due to a deemed dividend to preferred stockholders. Additionally, XOMA's assets have recently grown to over 120, including 14 registrational/Phase 3 programs and 7 commercial assets, but with recent negative news surrounding some of its assets and investors stepping to the sidelines, the valuation disconnect on even small number of assets is becoming increasingly evident. Furthermore, while XOMA's recent acquisition of Generation Bio provides potential future benefits, it also adds to their excess cash balance, which may lead to distribution to shareholders. Overall, XOMA's creativity in driving the number of partnered assets and bringing in cash in a non-dilutive manner, along with its approved revenue-generating assets and deep early-stage portfolio, are impressive, but the negative news and uncertainties surrounding some of its assets and valuation concerns contribute to a negative outlook on the stock.